References
1. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Anderson TJ, Gregoire J, Pearson GJ et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol 2016;32:1263-82.
3. Waters DD, Brotons C, Chiang CW, et al. Lipid Treatment Assessment Project 2:Amultinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009;120:28-34.
4. Saposnik G, Goodman SG, Leiter LA, et al. Applying the evidence: Do patients with stroke, coronary artery disease, or both achieve similar treatment goals? Stroke 2009;40:1417-24.
5. Hackam DG, Leiter LA, Yan AT, et al. Missed opportunities for secondary prevention of cardiovascular disease in Canada. Can J Cardiol 2007; 23:1124-30.
6. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119:676-83.
7. Banegas JR, Vegazo O, Serrano P, et al. The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain. Atherosclerosis 2006;188:420-4.
8. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high risk elderly patients: the treatment-risk paradox. JAMA 2004;291:1864-970.
9. Petrella RJ, Merikle E, Jones J. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis. Clin Ther 2007;29: 742-50.
10. Rapezzi C, Biagini E, Bellis P, et al. Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. J Cardiovasc Med 2008; 9:878-87.
11. Langer A, Tan M, Goodman SG, Gregoire J, Lin PJ, Mancini GBH, Stone JA, Wills C, Spindler C, Leiter LA GOAL Canada: Physician Education and Support Can Improve Patient Management CJC Open 2020;2:49-54.
12. Leiter LA, Berard L, Bowering K, et al. Type 2 Diabetes Mellitus Management in Canada: Is It Improving? Can J Diabetes 37 (2013) 82e89
13. Goodman SG, Langer A, Bastien NR, et al. Prevalence of dyslipidemia in statin treated patients in Canada: results of the Dyslipidemia International Study (DYSIS). Can J Cardiol 2010;26:e330e5.
14. Chen G, Farris MS, Cowling T, Colgan SM, Xiang P, Pericleous L, Rogoza RM, Tai MH, Anderson T. Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta. Can J Cardiol. 2019 Jul;35(7):884-891
15. Grima DT, Leiter LA, Goodman SG, Attard CL, Chow CM, Langer A. How Many Cardio vascular Events Can Be Prevented With Optimal Management of High-Risk Canadians? Can J Cardiol 2008;24(5):363-68.
17. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. The New England journal of medicine. 2015
18. Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376:1713-22
19. Schwartz GG, Szarek M, Bhatt DL et al. The ODYSSEY OUTCOMES Trial: Topline Results. Alirocumab in Patients After Acute Coronary Syndrome. Presented at the American College of Cardiology Annual Scientific Sessions March 10, 2018
20. Langer A, Tan M, Cieza T et al. Can Clinical Reminder Help Optimize the Use of Secondary Prevention Therapies in Non-ST Elevation Acute Coronary Syndrome? Int J Cardiol Cardiovasc Med 2017;1:1-5..
21. Katz PM, Mendelsohn AA, Goodman SG, Langer A, Teoh H, Leiter LA, Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Can J of Cardiol; 2011(27):138–145.
22. Tsang JLY, Mendelsohn A, Tan MKK, et al. Discordance between physicians’ estimation of patient cardiovascular risk and use of evidence-based medical therapy. Am J Cardiol 2008;102:1142-1145
23.Rogers AM, Ramanath VS, Grzybowski M, et al The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology’s Guidelines Applied in Practice (GAP) initiative in Michigan. Am Heart J. 2007;154:461–469.
24. Arnold SV, Spertus JA, Masoudi FA, et al Beyond Medication Prescription as Performance Measures. J Am Coll Cardiol 2013;62:1791-1801
25. Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-77. 26. Stephen J. Nicholls, MBBS, PhD1,2; Rishi Puri, MBBS, PhD2; Todd Anderson, MD3, Steven E. Nissen, MD2 et al. Effect of Evolucomab on Coronary Disease Progression in Statin Treated Patients. JAMA. 2016; 16(22): 2373-2384.
27. ESC/EAS task force: 2019 Guidelines for the management of dyslipidemias; Eur. Soc. Of Cardiology; Jan 1 2020: 41(1)
28. Cannon C, Blazing M. Ezetimibe add to Statin therapy after Acute Coronary Syndromes. N Eng J Med 2015; 372:2387-2397
29. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical Inertia in Response to Inadequate Glycemic Control: Do Specialists Differ From Primary Care Physicians? Diabetes Care 2005 Mar;28(3):600-6.
DISCLOSURES:
AL has received on behalf of the Canadian Heart Research Centre research grant support from Actelion, Amgen, Bayer, BMS, Merck, Novo Nordisk, Pfizer, Servier and Sanofi .
GBJM has received grants and/or honoraria from Amgen, Sanofi, HLS Therapeutices, Esperion, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen/Johnson & Johnson, Novartis, Novo Nordisk.
LAL has received research grant support from Astra Zeneca, Amgen, Kowa, The Medicines Company, and Sanofi. He has also served as a consultant for Astra Zeneca, Amgen, Esperion, HLS, Merck, The Medicines Company, and Sanofi
JG has received speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Ferring Pharmaceuticals, HLS Therapeutics, Janssen/Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Sunovion;
SGG has received Research grant support (e.g., steering committee or data and safety monitoring committee) and/or speaker/consulting honoraria (e.g., advisory boards) from: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Merck, Novartis, Novo Nordisk A/C, Pfizer, Regeneron, Sanofi, Servier; and salary support/honoraria from the Heart and Stroke Foundation of Ontario/University of Toronto (Polo) Chair, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, and PERFUSE Research Institute.JAS has received research support from Sanofi and has served as a consultant and/or speaker for Astrazeneca, Amgen, Bayer, HLS Therapeutics, Lilly, Novartis, Novo-Nordisk, and Sanofi.
Mary Tan has no disclosures.
PJL has been a consultant or speaker for AstraZeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Merck, Sanofi, Amgen, Novo Nordisk, GSK and HLS Therapeutics